Grifols Biotest Holdings GmbH Announces Tender Offer for Biotest AG

Grifols Biotest Holdings GmbH recently declared its intention to acquire all common and preferred shares of Biotest AG through a public delisting purchase offer. Effective March 31, 2025, the bid includes EUR 43.00 per common share and EUR 30.00 per preferred share, targeting all no-par bearer shares.

The strategy involves delisting Biotest shares from the Frankfurt Securities Exchange, with a deadline set 10 workdays before the offer's expiration. Regulatory measures ensure the transition aligns with German legal frameworks, as outlined by the WpÜG and BörsG acts.

Interested stakeholders should consult the forthcoming Offering Document, which will detail the acquisition, following approval from the Federal Financial Supervisory Authority. This document will be accessible on Grifols' official website. Compliance with local legal requirements is advised for shareholders outside the European Union.